20th Sep 2018 13:47
LONDON (Alliance News) - Netscientific PLC said Thursday said ProAxsis Ltd, a company in its portfolio, had two products selected for inclusion in an upcoming medical trial funded by the European Respiratory Society.
The BRIDGE study will employ ProAxsis' NEATstik, the first ever test developed to enable measurement of active neutrophil elastase at point-of-care.
The study will also use ProAxsis' ProteaseTag Active NE Immunoassay over three years in 1000 patients suffering from bronchiectasis across Europe.
The study hopes to assess microbiome, proteomics, detailed phenotyping, and imaging, in order to explore new biomarkers and determine their impact on clinical outcomes.
NetScientific holds a 54% stake in ProAxsis.
NetScientific Chief Executive Officer and ProAxsis Chairman Francois Martelet said: "BRIDGE will be a major respiratory study and we are pleased that the ERS, a prominent research body, has selected ProAxsis' respiratory immunoassays for inclusion.
"ProAxsis has demonstrated that active neutrophil elastase can help identify bronchiectasis patients at highest risk of clinical exacerbations, so we are excited for the opportunity to explore this and other potential biomarkers in a large, pan-European patient population. This decision further validates the use of these immunoassays in the respiratory field, and we expect to see this translate into further engagement with pharmaceutical companies that are active in the area."
Shares in Netscientific were untraded Thursday but last closed at 28.00 pence each.
Related Shares:
Netscientific